Selected article for: "acute respiratory syndrome and economic development"
Author: Yu, Sicong; Chen, Keda; Fang, Lei; Mao, Haiyan; Lou, Xiuyu; Li, Chaonan; Zhang, Yanjun
Title: Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
  • Cord-id: sgdhsy1r
  • Document date: 2021_6_2
    • ID: sgdhsy1r
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV) pose a great threat to humanity. Every pandemic involving these coronaviruses has seriously affected human health and economic development. Currently, there are no approved therapeutic drugs against their infections. Therefore, the development of vaccines is particularly important to combat these coronaviruses. In this
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV) pose a great threat to humanity. Every pandemic involving these coronaviruses has seriously affected human health and economic development. Currently, there are no approved therapeutic drugs against their infections. Therefore, the development of vaccines is particularly important to combat these coronaviruses. In this review, we summarized and analyzed the progress of vaccines against SARS-CoV, MERS-CoV, and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, nucleic acid vaccines, and viral vector vaccines. In addition, we compared the levels of neutralizing antibodies in the serum of patients with these three kinds of coronaviruses at different stages, and their ability and effects against SARS-CoV-2, MERS-CoV, and SARS-CoV. This review provides useful information for vaccine evaluation and analysis.

    Search related documents:
    Co phrase search for related documents
    • accession number and adenovirus type: 1
    • accession number and adenovirus vaccine: 1
    • accession number and adenovirus vector: 1
    • accession number and live vaccine: 1
    • accession number and live virus: 1
    • accessory protein and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein and live vaccine: 1
    • accessory protein and live virus: 1, 2
    • acid vaccine and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acid vaccine and adenovirus type: 1
    • acid vaccine and adenovirus vector: 1
    • acid vaccine and adjuvant vaccine: 1, 2, 3, 4
    • acid vaccine and live vaccine: 1, 2, 3, 4, 5, 6, 7, 8
    • acid vaccine and live virus: 1, 2
    • acute respiratory syndrome coronavirus and adenovirus type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute respiratory syndrome coronavirus and adenovirus vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory syndrome coronavirus and adjuvant group: 1, 2
    • acute respiratory syndrome coronavirus and adjuvant vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25